Composite Plant Extract Formulation Inhibiting Coronavirus Replication

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is no effective vaccine or antiviral drug available to prevent or treat human coronavirus infections, particularly those belonging to the family Coronaviridae, which have high morbidity and replication rates.

Innovation Solution

A novel pharmaceutical formulation comprising Centella asiatica, Withania somnifera, Andrographis paniculata, starch, magnesium stearate, and PVP K30, which inhibits the replication of viruses belonging to the family Coronaviridae, including SARS-CoV-2, through oral administration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional antiviral drugs or vaccines are used, then viral replication can be controlled, but no effective treatment exists for Coronaviridae infections

Engineering Contradiction:

Improveeffectiveness of antiviral treatmentVSAvoidavailability of treatment options

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent combines multiple plant extracts (Centella asiatica, Withania somnifera, and Andrographis paniculata) into a composite pharmaceutical formulation. This composite approach leverages the synergistic effects of different botanical compounds to achieve antiviral activity against Coronaviridae, where no single conventional antiviral drug has been effective.

Inventive Principle:

Principle #40Composite materials

2Reliability

If vaccines are developed to prevent viral infections, then immunity can be conferred, but no vaccines are available for human coronavirus infections

Engineering Contradiction:

Improveprotection against viral infectionVSAvoidtime for vaccine development and deployment

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent employs plant extracts that have demonstrated preliminary antiviral activity through traditional use and modern research. These extracts can be administered directly to provide immediate protective effects without requiring the extended time needed for vaccine development, clinical trials, and regulatory approval.

Inventive Principle:

Principle #10Preliminary action

3Productivity

If antiviral drugs are administered to inhibit virus replication, then viral load can be reduced, but existing drugs are ineffective against Coronaviridae

Engineering Contradiction:

Improveinhibition of viral replicationVSAvoidefficacy of antiviral medication

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent utilizes compounds from plant extracts that exhibit antiviral activity through multiple mechanisms of action, including inhibition of viral entry, replication, and assembly. This multi-target approach changes the therapeutic parameters by addressing various stages of the viral lifecycle, thereby achieving reliable inhibition of Coronaviridae replication where single-target conventional drugs have failed.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12280082B2Formulation for inhibiting virus replication

Publication Date: 2025.04.22 GANJU SHIBBAN KRISHEN

AI summary

The present invention is related to a novel formulation comprising active pharmaceutical ingredients, optionally in combination with other active pharmaceutical ingredients which are capable of inhibiting replication of the virus belonging to the family Coronaviridae. The present invention formulation includes Andrographis paniculata, PVP K30 and Acrylic polymer. The present invention further relates to different pharmaceutical formulations that have different modes of application.